Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 424 of 6351
-
Can special glasses or eyedrops stop kids' eyesight from getting worse?
Disease control Recruiting nowTo date, randomized trials of low-concentration atropine eyedrops and specially designed spectacle lenses to slow the progression of myopia are limited in number and results are inconsistent in non-Asian children. Although results of some recent randomized clinical trials outsid…
Phase 3 • Sponsor: Jaeb Center for Health Research • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Bladder cancer showdown: can radiation and chemotherapy match surgery?
Disease control Not yet recruitingYour text is mostly clear and well-structured. Here's a slightly polished version for improved clarity and flow: This is a randomized, non-inferiority study comparing radiochemotherapy to radical cystectomy in patients with muscle-invasive bladder cancer. The primary outcome is …
Sponsor: Brazilian Clinical Research Institute • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New study aims to shield aging brains from Surgery's mental fog
Prevention Not yet recruitingNeurocognitive complications, mainly delirium and neurocognitive disorders, are common cerebral complications in older patients after surgery and associated with worse long-term outcomes. An ongoing 2×2 factorial trial conducted by the investigators plan to test the effects of pe…
Phase 4 • Sponsor: Peking University First Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:32 UTC
-
New hope for tough lymphoma: Triple-Drug attack
Disease control Recruiting nowAn Open-Label, Single-Arm, Multicenter Phase II Clinical Study to Evaluate the Efficacy of Azacitidine, Chidamide, and PD-1 Monoclonal Antibody in the Treatment of Refractory/Relapsed Peripheral T-Cell Lymphoma.
Early phase 1 • Sponsor: Second Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Immunotherapy plus chemo may open door to surgery for inoperable lung cancer
Disease control Not yet recruitingThis is a prospective, single-center phase II study evaluating sintilimab plus chemotherapy as induction therapy for unresectable stage IIIC non-small cell lung cancer (NSCLC). Treatment-naive eligible patients who signed informed consent were enrolled after MDT screening. Patien…
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New combo targets tough lymphoma subtypes in early trial
Disease control Recruiting nowThis is a prospective, open-label, single-arm, single-center, Phase II clinical study designed to evaluate the efficacy and safety of Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients …
Phase 2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug targets hidden heart risk in people with high lp(a)
Disease control Recruiting nowLipoprotein(a), also known as Lp(a), is a protein that carries cholesterol and proteins in your blood. People with high Lp(a) have a higher risk for heart disease. The main purpose of the study is to investigate how lepodisiran, compared to a placebo, affects the amount and type …
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Genetic test may guide chemo choice for pancreatic cancer patients
Disease control Not yet recruitingPancreatic ductal adenocarcinoma (PDAC) exhibits significant heterogeneity, making the optimal choice of chemotherapy challenging. While targeted therapies benefit from companion biomarkers, few tools exist to guide the selection of cytotoxic chemotherapy. Transcriptomic signatur…
Phase 2 • Sponsor: Federation Francophone de Cancerologie Digestive • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Promising drug cocktail aims to shrink aggressive nasal tumors before surgery
Disease control Not yet recruitingT4 stage sinonasal adenoid cystic carcinoma (SNACC) is a rare but aggressive cancer in the nasal cavity and sinuses. These tumors often invade the skull base, eye socket, or brain covering (dura), making complete surgical removal difficult and carrying a high risk of recurrence e…
Phase 2 • Sponsor: Eye & ENT Hospital of Fudan University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Sound waves vs X-Rays: which guides heart stents better?
Disease control Not yet recruitingSTEMI represents the subtype of ACS with the worst prognosis, associated with high mortality and an elevated risk of complications. The use of IVI guidance holds the potential to reduce the incidence of MACE. In previous studies, there has been limited research on intravascular i…
Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a common vitamin a drug tame a deadly immune storm?
Disease control Not yet recruitingThis study is designed to evaluate the safety and preliminary efficacy of all-trans retinoic acid (ATRA) as an initial treatment for patients with active hemophagocytic lymphohistiocytosis (HLH). HLH is a severe hyperinflammatory syndrome caused by excessive activation of immune …
Phase 2/3 • Sponsor: Beijing Anzhen Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New combo therapy aims to wipe out leukemia cells for good
Disease control Stopped earlyThe purpose of this study is to determine the feasibility, safety, and efficacy of a combination therapy in the treatment of B-cell acute lymphoblastic leukemia (B-ALL) based on multi-antigen-targeted chimeric antigen receptor T cells (CAR-T) followed by engineered immune effecto…
Phase 1 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Engineered immune cells take aim at two cancer targets
Disease control Stopped earlyThe purpose of this clinical trial is to assess the feasibility, safety and efficacy of anti-GD2/CD56 bi-specific CAR-T cell therapy in patients with GD2 and/or CD56 positive cancer. Another goal of the study is to learn more about the function of the anti-GD2/CD56 bi-specific CA…
Phase 1/2 • Sponsor: Shenzhen Geno-Immune Medical Institute • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Precision radiotherapy targets rare breast tumors by genetic fingerprint
Disease control Not yet recruitingPhyllodes tumor (PT) of the breast is a rare fibroepithelial neoplasm, and the role of postoperative radiotherapy (PORT) remains controversial. Our team has previously established a molecular subtyping system for PT, classifying patients into four subtypes. Among them, the malign…
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Electric pulses aim to tame type 2 diabetes
Disease control Recruiting nowexperiment design: Single-center, single-arm, open-label trial Inclusion Criteria: 1. Ages 18-70. 2. At least 6 months prior to enrollment, the patient must have been diagnosed with type 2 diabetes mellitus. 3. The glycated hemoglobin level is 7.5%-10.5%. 4. BMI 2 7-40 kg/m2. 5…
Sponsor: Shanghai East Hospital • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Heart scan AI could predict sudden cardiac death risk in common heart condition
Knowledge-focused OngoingHypertrophic cardiomyopathy (HCM) is one of the leading causes of sudden cardiac death (SCD), particularly in young and middle-aged individuals. Current arrhythmic risk stratification mainly relies on clinical and imaging-based models, including the ESC HCM Risk-SCD score and gui…
Sponsor: Centro Cardiologico Monzino • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
AI reads MRI scans to predict who will benefit from chemo
Diagnosis Recruiting nowThis study is a multicenter, prospective, observational cohort study to evaluate the predictive performance of pre-treatment DCE-MRI-based artificial intelligence (AI) models for neoadjuvant chemotherapy benefit in HR+/HER2- breast cancer. The study plans to enroll eligible HR+/H…
Sponsor: Fujian Cancer Hospital • Aim: Diagnosis
Last updated Jul 16, 2026 00:00 UTC
-
Could a common gout pill protect hearts in HIV?
Disease control Recruiting nowThe purpose of this study is to evaluate whether colchicine can reduce coronary artery inflammation in people living with HIV and high cardiovascular risk. Participants will be randomized 1:1 to receive either colchicine or placebo for 96 weeks in a double-blind, multicenter clin…
Phase 2 • Sponsor: Instituto de Investigación Hospital Universitario La Paz • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
A second look: MRI screening may spot hidden prostate cancers
Prevention Recruiting nowProstate cancer remains one of the leading causes of cancer-related morbidity and mortality among men. While PSA-based screening has been associated with reduced prostate cancer mortality, it also results in substantial overdiagnosis and overtreatment of clinically insignificant …
Sponsor: University Hospital, Basel, Switzerland • Aim: Prevention
Last updated Aug 15, 2026 00:00 UTC
-
Can a new PET tracer outsmart head and neck cancer metastases?
Diagnosis CancelledThe purpose of this study is to determine the diagnostic utility of 89Zr-panitumumab to identify metastatic lesion(s) in subjects with head and neck squamous cell carcinoma (HNSCC).
Phase 2 • Sponsor: Andrei Iagaru • Aim: Diagnosis
Last updated Aug 19, 2026 00:00 UTC